Oral News and Research

RSS

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals Inc. today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation.

13 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Study highlights disparities in access to diabetes treatment in European countries

Hundreds of thousands of people living with diabetes in Europe do not have access to the treatment they need, putting their health at risk. These are the initial findings of a study by the International Diabetes Federation Europe on Access to Quality Medicines and Medical Devices for Diabetes Care in Europe.

13 Nov 2013

XTANDI now accepted for use within NHS Scotland for treatment of adult men with mCRPC

The Scottish Medicines Consortium, which advises NHS Scotland on prescribing new treatments, announced today that XTANDI (enzalutamide) is accepted for unrestricted use within NHS Scotland for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

13 Nov 2013

Global Coalition Against Child Pneumonia calls for continued investment in innovations, proven tools

Global health advocates today commemorated the fifth annual World Pneumonia Day by calling on global leaders to scale up existing interventions and invest in new diagnostics and treatments to defeat pneumonia. Each year, pneumonia kills more children than AIDS, malaria and tuberculosis combined. Pneumonia took the lives of nearly 1.1 million children under 5 in 2012 alone, with more than 99 percent of these deaths in developing countries, where access to healthcare facilities and treatment is out of reach for many children.

12 Nov 2013

Study provides new evidence underlining the significance of bitter taste perception

It's no coincidence that the expression "to leave a bitter taste in one's mouth" has a double meaning; people often have strong negative reactions to bitter substances, which, though found in healthful foods like vegetables, can also signify toxicity. For this reason, the ability to sense bitterness likely played an important role in human evolution.

12 Nov 2013

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.

12 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.

11 Nov 2013

Recent studies suggest that controlling dietary acid intake may help improve kidney health

Three new studies suggest that controlling dietary acid intake could help improve kidney health. Results of these studies will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.

11 Nov 2013

Drug formulation services for highly potent active pharmaceutical ingredients provided by Evonik

Evonik Industries has broadened its capabilities in finished drug product formulation and clinical supply manufacturing and can now handle drug products containing highly potent active pharmaceutical ingredients (HPAPIs) in Darmstadt, Germany, and Birmingham, Alabama/USA. Investments in high containment facilities and upgrades in the laboratory and GMP areas in Birmingham enable Evonik to handle HPAPIs with occupational exposure limits (OEL) as low as 0.1μg/m3 and in Darmstadt as low as 1 μg/m3. Starting 2014, OEL as low as 0.1μg/m3 will also be possible in Darmstadt.

8 Nov 2013

New outbreak of polio in Syria may endanger neighbouring regions, warn experts

Two infectious disease experts have written to The Lancet warning that a new outbreak of polio (due to infection with wild-type polio virus 1, WPV1) in Syria, recently confirmed by WHO, might endanger neighbouring regions, including Europe.

8 Nov 2013

Life-saving bone marrow transplants may also cure peanut allergies

Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's Annual Scientific Meeting, a 10-year-old boy no longer had a peanut allergy after undergoing a bone marrow transplant.

8 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

People with food allergy may no longer have to avoid food entirely

Have food allergies? If you answered yes, you know the best way to prevent a severe allergic reaction is to totally avoid the offending food. But according to a presentation at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), you may no longer have to avoid the food entirely.

8 Nov 2013

Oral News and Research

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Study highlights disparities in access to diabetes treatment in European countries

XTANDI now accepted for use within NHS Scotland for treatment of adult men with mCRPC

Global Coalition Against Child Pneumonia calls for continued investment in innovations, proven tools

Study provides new evidence underlining the significance of bitter taste perception

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Recent studies suggest that controlling dietary acid intake may help improve kidney health

Drug formulation services for highly potent active pharmaceutical ingredients provided by Evonik

New outbreak of polio in Syria may endanger neighbouring regions, warn experts

Life-saving bone marrow transplants may also cure peanut allergies

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

People with food allergy may no longer have to avoid food entirely

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

New Asian poll highlights major considerations when managing Type 2 Diabetes

New treatment option for patients with most difficult-to-treat forms of hepatitis C

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News